Search

Your search keyword '"Konno, O."' showing total 28 results
Start Over Author "Konno, O." Journal transplantation proceedings
28 results on '"Konno, O."'

23. Safety and Efficacy of Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Graceptor) in Stable Kidney Transplant Recipients

Author

Nakamura, Y., primary, Hama, K., additional, Katayama, H., additional, Soga, A., additional, Toraishi, T., additional, Yokoyama, T., additional, Kihara, Y., additional, Jojima, Y., additional, Konno, O., additional, Iwamoto, H., additional, Takeuchi, H., additional, Hirano, T., additional, and Shimazu, M., additional

Published
2012
Full Text
View/download PDF

26. The Role of Plasmapheresis Therapy for Perioperative Management in ABO-Incompatible Adult Living Donor Liver Transplantation

Author

Ashizawa, T., primary, Matsuno, N., additional, Yokoyama, T., additional, Kihara, Y., additional, Kuzuoka, K., additional, Taira, S., additional, Konno, O., additional, Jyojima, Y., additional, Akashi, I., additional, Nakamura, Y., additional, Hama, K., additional, Iwamoto, H., additional, Iwahori, T., additional, Nagao, T., additional, Kasahara, M., additional, and Tanaka, K., additional

Published
2006
Full Text
View/download PDF

27. Evidence of Different Pharmacokinetics Between Cyclosporine and Tacrolimus in Renal Transplant Recipients: Why Cyclosporine Is Monitored by C2 Level and Tacrolimus by Trough Level

Author

Takeuchi, H., Matsuno, N., Hirano, T., Toraishi, T., Konno, O., Nakamura, Y., Iwamoto, H., Hama, K., Unezaki, S., and Nagao, T.

Subjects
*PHARMACOKINETICS, *KIDNEY transplant patients, *CYCLOSPORINE, *TACROLIMUS, *DRUG monitoring, *PHOSPHOPROTEIN phosphatases
Abstract

Abstract: The clinical efficacy of calcineurin inhibitors administered to renal transplant recipients is considered to be a strong function of the area under the concentration time curve (AUC). Monitoring of blood concentrations for two similar calcineurin inhibitors, cyclosporine (CyA) and tacrolimus (TAC) are different. Namely, CyA blood concentration is usually monitored at two hours after administration (C2), a surrogate for peak concentration (Cp), and TAC at trough concentration (Ct). We examined the behavior of blood concentration curves simultaneously for both CyA and TAC in renal transplant recipients with similar clinical backgrounds. Furthermore, we analyzed the correlation of Cp and Ct vs AUC implementing an area under the trough level, or area above the trough level as new pharmacokinetic parameters, so that C2 for CyA and Ct for TAC has validated using controlled clinical data. We observed differences in the pharmacokinetics between, [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

28. First Multicenter Clinical Trial on Machine Perfusion Preservation for Marginal Donor Kidney Transplantation in Japan.

Author

Iwamoto H, Matsuno N, Konno O, Nakamura Y, Ishii Y, Tokodai K, Kashiwadate T, Miyagi S, Kusaka M, Ito T, and Kenmochi T

Subjects
Humans, Middle Aged, Japan, Creatinine, Graft Survival, Organ Preservation, Tissue Donors, Perfusion adverse effects, Kidney Transplantation adverse effects, Tissue and Organ Procurement
Abstract

Background: Machine perfusion has not been widely used because of its low demand in Japan; however, we believe its advantages may increase the number of organ transplants., Methods: Here, we report the first clinical trial of machine perfusion for kidney transplantation in Japan. We used the CMP-X08 perfusion device (Chuo-Seiko Co, Ltd, Asahikawa, Hokkaido, Japan) to preserve the donated organs. The flow rate, perfusion pressure, renal resistance, and temperature were monitored during continuous hypothermic perfusion., Results: From August 2020 to the present, 13 cases of perfusion-preserved kidney transplantation have been performed. Of these, ten and 3 cases were performed using organs donated after brain death (DBD) and cardiac death (DCD), respectively. The average age of the recipients was 55.9 ± 7.3 (45-66) years. The average dialysis period was 14.8 ± 8.4 (0-26) years. The donor's final creatinine level before organ retrieval was 1.58 ± 1.0 (0.46-3.07) mg/dL. The warm ischemic times of the 3 DCD donors were 3, 12, and 18 minutes. The average total ischemic time was 12.0 ± 3.7 (7.17-19.88) hours. The average MP time was 140 (60-240) minutes. A total of 7 cases had delayed graft function. The best creatinine level during hospitalization was 1.17 ± 0.43 (0.71-1.85) mg/dL. There were no primary non-functional cases, and perfusion preservation was safely performed in all cases., Conclusions: Therefore, we present this report as the first clinical trial on machine perfusion for kidney transplantation from marginal donors with DBD and DCD in Japan., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results